Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Clinical trial NCT03671590 · TERMINATED
Trial details
- NCT number
- NCT03671590
- Sponsor
- TG Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-10
- Primary completion
- 2024-05-21
- Enrollment
- 172
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.